Bordier Bruno B, Marion Patricia L, Ohashi Kazuo, Kay Mark A, Greenberg Harry B, Casey John L, Glenn Jeffrey S
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 269 Campus Drive, Palo Alto, CA 94305-5187, USA.
J Virol. 2002 Oct;76(20):10465-72. doi: 10.1128/jvi.76.20.10465-10472.2002.
Hepatitis delta virus (HDV) causes both acute and chronic liver disease throughout the world. Effective medical therapy is lacking. Previous work has shown that the assembly of HDV virus-like particles (VLPs) could be abolished by BZA-5B, a compound with farnesyltransferase inhibitory activity. Here we show that FTI-277, another farnesyltransferase inhibitor, prevented the production of complete, infectious HDV virions of two different genotypes. Thus, in spite of the added complexity and assembly determinants of infectious HDV virions compared to VLPs, the former are also sensitive to pharmacological prenylation inhibition. Moreover, production of HDV genotype III virions, which is associated with particularly severe clinical disease, was as sensitive to prenylation inhibition as was that of HDV genotype I virions. Farnesyltransferase inhibitors thus represent an attractive potential class of novel antiviral agents for use against HDV, including the genotypes associated with most severe disease.
丁型肝炎病毒(HDV)在全球范围内均可引发急性和慢性肝病。目前缺乏有效的药物治疗方法。先前的研究表明,具有法尼基转移酶抑制活性的化合物BZA-5B可抑制HDV病毒样颗粒(VLP)的组装。在此我们表明,另一种法尼基转移酶抑制剂FTI-277可阻止两种不同基因型的完整、有传染性的HDV病毒粒子的产生。因此,尽管与VLP相比,传染性HDV病毒粒子的结构更为复杂且具有组装决定因素,但前者对药理学异戊二烯化抑制也很敏感。此外,与特别严重的临床疾病相关的HDV基因型III病毒粒子的产生,对异戊二烯化抑制的敏感性与HDV基因型I病毒粒子相同。因此,法尼基转移酶抑制剂是一类有吸引力的新型抗病毒药物,可用于对抗HDV,包括与最严重疾病相关的基因型。